Clinical Trials Logo

Ulcerative Colitis clinical trials

View clinical trials related to Ulcerative Colitis.

Filter by:

NCT ID: NCT00360022 Terminated - Ulcerative Colitis Clinical Trials

Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)

Start date: August 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the program that has been made to ease the transition of care for adolescent patients with IBD from pediatric gastroenterology to adult gastroenterology is effective to reduce the risk of disease flare during this period. Patient satisfaction with this program will also be assessed.

NCT ID: NCT00355901 Terminated - Ulcerative Colitis Clinical Trials

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Start date: September 2006
Phase: Phase 2
Study type: Observational

To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.

NCT ID: NCT00349388 Terminated - Ulcerative Colitis Clinical Trials

Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients

Start date: July 2006
Phase: N/A
Study type: Interventional

To determine whether once a day administration of Mesalamine is at least as safe and efficacious and administration of multiple doses a day in preventing clinical relapse of ulcerative colitis in children and adolescence.

NCT ID: NCT00307827 Terminated - Ulcerative Colitis Clinical Trials

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.

NCT ID: NCT00296556 Terminated - Ulcerative Colitis Clinical Trials

Therapeutic Study of ONO-4819CD for Ulcerative Colitis

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether ONO-4819CD is safe and effective in the treatment of mild to moderate ulcerative colitis.

NCT ID: NCT00279435 Terminated - Ulcerative Colitis Clinical Trials

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Start date: August 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.

NCT ID: NCT00279422 Terminated - Ulcerative Colitis Clinical Trials

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Start date: February 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.

NCT ID: NCT00268164 Terminated - Ulcerative Colitis Clinical Trials

Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the lactic acid bacteria " Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis (BB12)" is effective as maintenance treatment in ulcerative colitis.

NCT ID: NCT00254618 Terminated - Ulcerative Colitis Clinical Trials

A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.

Start date: October 2005
Phase: Phase 1
Study type: Interventional

The purpose of this randomized, open-label, parallel-group study is to determine how the body absorbs and eliminates mesalamine following administration of either 30 mg/kg/day, 60 mg/kg/day or 90 mg/kg/day as 400 mg delayed-release tablets given every 12 hours of 28 days to children and adolescents with active ulcerative colitis.

NCT ID: NCT00209287 Terminated - Ulcerative Colitis Clinical Trials

Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis

Start date: June 2005
Phase: Phase 4
Study type: Interventional

Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day. Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at the inclusion. Signed informed consent form.